Pre-Ruxolitinib (66 days, 73 sleep periods)
HR: 85.1 bpm · HRV: 9.1 ms
Post-Ruxolitinib (7 days, 11 sleep periods)
HR: 81.8 bpm · HRV: 10.1 ms
Key finding: Ruxolitinib produced a statistically significant temperature response within 7 days (p=0.009, 99% posterior probability). 1/11 streams show p<0.1. UKF: Cardiac Reserve shift p=0.0398, Sleep Quality shift p=0.0000, Lowest HR p=0.126.
Temperature
Effect: -0.24°C
HRV (RMSSD)
9.2ms
vs healthy 42-49 ms | Kleiger 1987 / Bigger 1992
Resting HR
85bpm
Lowest HR p=0.126
SpO2
96.4%
BOS risk: MODERAT (24/100)
Sleep Efficiency
73%
Below 85% threshold
Autonomic Tone
1.09SD
UKF state | improved | p=0.244
GVHD Score
15/100
7d avg: 22
Anomaly Days
8/84
Feb 9 detected (80% sensitivity)
Loading disease states...
Loading anomaly timeline...
Loading biomarker trends...
Loading SpO2/BOS panel...
Loading biosignal timeline...
Loading HR terrain map...
Loading circadian radar...
Methodology
Data source: Oura Ring Gen 4, 29,263 HR readings, 5,986 HRV samples,
6,382 sleep epochs.
Analysis: CausalImpact (BSTS), Unscented Kalman Filter (5 latent states), rSLDS (4 disease states),
5-algorithm anomaly ensemble, 6 composite biomarkers, Chronos-2/ARIMA forecasting.
Sleep architecture: Deep: 14.9% Light: 51.3% REM: 11.5% Awake: 22.3%
For research and clinical discussion only. Not a diagnostic tool.